The capital injection was provided by U.S. investment firm OrbiMed, and the Swiss dental manufacturer explained in a press release that the two companies share the vision of developing vVARDIS into a leading supplier of innovative dental products. As the market transitions from invasive to noninvasive care and the adoption of artificial intelligence-driven detection of early tooth decay accelerates, vVARDIS products are well aligned with current market trends, vVARDIS said.

Matthew Rizzo, a partner at OrbiMed, commented: “We are confident that vVARDIS has the scientific knowledge and capabilities to become a global powerhouse in the dental market [...] The growth ambition of the company and its focus on providing innovative solutions in a global dental market are at the core of our investment strategy.”

Drs. Haley and Goly Abivardi, founders and co-CEOs of vVARDIS, shared their excitement about the partnership, stating that OrbiMed’s funding and expertise will help advance vVARDIS’s mission to provide early caries treatment that is pain-free, regenerative and accessible. They said: “Dental professionals have been waiting for decades for a drill-free treatment of early decay. Curodont has the potential to broaden the scope of options offered by dental practices and empower them to enhance patient care.”

Tags: